Clinical Trial Detail

NCT ID NCT02719574
Title Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Forma Therapeutics, Inc.

myelodysplastic syndrome

acute myeloid leukemia


Cytarabine + Olutasidenib


Azacitidine + Olutasidenib

Age Groups: adult

Additional content available in CKB BOOST